V̇/Q̇ 失匹配:COPD 治疗的新靶点
本文为特邀综述,围绕 COPD 患者因肺泡通气(V̇A)与毛细血管灌注(Q̇c)异常导致的气体交换效率下降,梳理其与活动相关呼吸困难及运动不耐受的关系。文章回顾了主要作用于 V̇A 或 Q̇c 的现有治疗证据,并提出深化表型分析与评估改善气体交换效率的药物两个研究方向。
要点
- COPD 早期和轻度阶段即可出现 V̇A、Q̇c 或两者异常,并常伴活动相关呼吸困难与运动不耐受。
- 低 V̇A/Q̇c 所致静脉血掺杂或高 V̇A/Q̇c 所致无效通气,均可解释呼吸困难与运动耐受下降。
- 现有主要作用于 V̇A 或 Q̇c 的治疗证据存在矛盾,气体交换效率作为靶点尚待研究。
核心结论
- COPD 的气体交换效率下降可能由 V̇A、Q̇c 或两者异常引起,并伴随活动相关呼吸困难与运动不耐受等临床后果。
- 现有主要作用于 V̇A 或 Q̇c 的治疗对气体交换效率与运动耐受的证据存在矛盾,神经化学传入活动增加作为治疗靶点仍不明确。
研究设计与样本
- 本文为特邀综述,总结 COPD 中 V̇A/Q̇c 异常与呼吸困难、运动耐受的关系及相关治疗证据。
主要发现
- COPD 早期和轻度阶段即可报告 V̇A、Q̇c 或两者异常。
- 低 V̇A/Q̇c 导致静脉血掺杂,高 V̇A/Q̇c 导致无效通气,或两者并存,可解释呼吸困难与运动耐受下降。
- 支持现有主要作用于 V̇A(支气管扩张剂、抗炎药物)或 Q̇c(口服与吸入血管扩张剂、阿米三嗪、补充氧)治疗气体交换效率与运动耐受的证据存在矛盾。
临床怎么用
- 临床应关注 COPD 患者气体交换效率异常,并将其与活动相关呼吸困难及运动不耐受联系起来评估。
- 现有主要作用于 V̇A 或 Q̇c 的治疗证据不一致,临床应用需结合患者具体情况判断。
局限性
- 本文为综述,未提供新的原始研究数据。
- 现有支持治疗改善气体交换效率与运动耐受的证据存在矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In people with COPD, pulmonary gas-exchange efficiency may be impaired because of abnormal alveolar ventilation (V˙A), capillary perfusion (Q˙c), or both. Both have been reported in early and mild stages of the disease. Such derangements often accompany significant clinical consequences such as activity-related dyspnea and exercise intolerance. Although much attention has been paid to pharmacologic treatment of mechanical abnormalities in COPD (eg, bronchodilators to deflate the lungs), increasing neurochemical afferent activity, secondary to gas-exchange inefficiency, has remained elusive as a therapeutic target. Hence, in this invited review, we first summarize how dyspnea, leading to poor exercise tolerance in COPD, may be explained by an increased venous admixture resulting from low V˙A/Q˙c, or wasted ventilation related to high V˙A/Q˙c, or both. We review the conflicting evidence supporting current treatments for gas-exchange inefficiency and exercise tolerance that act primarily on V˙A (bronchodilators, antiinflammatory medications) or Q˙c (oral and inhaled vasodilators, almitrine, and supplemental oxygen). Finally, to address the current knowledge and health care gaps, we propose two independent clinical research foci that may lead to a better understanding of the role of pulmonary gas-exchange inefficiency and activity-related dyspnea in COPD: (1) enhanced and deeper phenotyping of patients with COPD with V˙A/Q˙c abnormalities and (2) evaluation of existing and novel pharmacologic treatments to improve gas-exchange inefficiency, exertional dyspnea, and exercise tolerance across the spectrum of COPD severity.
引用
- Neder JA, Kirby M, Santyr G, et al. V̇/Q̇ Mismatch: A Novel Target for COPD Treatment. Chest. 2022. PMID: 35390329. doi:10.1016/j.chest.2022.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。